ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)

Study Purpose

This is a phase I/II, single-arm, open-lable study of autologous stem cell transplantation in combination with C-CAR088, an autologous BCMA CAR-T cell product, for patients with ulta high-risk multiple myeloma, defined as failed or unsatisfied responses to front line VRD-based treatment with or without the presence of multiple high-risk cytogenetic features.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 18 Years - 65 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Transplantation eligible patients, male or female, aged 18 to 65 years.
  • - Ultra high risk multiple myeloma, defined as failed or unsatisfied responses to front line VRD-based treatment with or without the presence of multiple high-risk cytogenetic features.
  • - Adequate liver, renal, bone marrow, and heart function.
  • - Eastern Cooperative Oncology Group (ECOG) Performance status 0-1.
  • - Male and female of reproductive potential must agree to use birth control during the study.

Exclusion Criteria:

  • - Known allergies to the components or excipients of the C-CAR088 cell product.
  • - Prior allogenic HSCT, or ASCT.
  • - CNS involvement.
  • - Stroke or convulsion history within 6 months prior to signing ICF.
  • - Autoimmune disease, immunodeficiency or disease requiring immunosuppressants treatment.
  • - Uncontrolled active infection; active HBV, HCV infection; HIV or syphilis Infection.
  • - Severe heart, liver, renal or metabolism disease.
  • - Inadequate wash-out time for previous anti-tumor treatments prior to apheresis.
  • - Previous CAR-T cell treatment, genetically modified T-cell therapies or BCMA-directed treatment history.
- History or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's safe participation and compliance in the trial

Trial Details

Trial ID:

This trial id was obtained from, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Institute of Hematology & Blood Diseases Hospital, China
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Dehui Zou, M.D., PH.D.
Principal Investigator Affiliation Institute of Hematology & Blood Diseases Hospital, China
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other, Industry
Overall Status Recruiting
Countries China

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Additional Details

Patients with ultra high-risk multiple myeloma will undergo leukapheresis, stem cell mobilization and collection (could omit if collected before screening), conditioning, ASCT and C-CAR088 infusion. Patients receive a single dose of C-CAR088 three days post-ASCT. Two conditioning protocols and two dose levels of C-CAR088 will be used based on the investigator's discretion. Patients will be evaluated closely for safety of efficacy during the first three months, then less frequently in the following months until 24 months post-ASCT.

Arms & Interventions


Experimental: ASCT and C-CAR088

Patients will undergo ASCT followed by C-CAR088 single dose infusion.


Procedure: - Autologous hematopoietic stem cell transplantation

Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection. If previously collected stem cells are available, no stem cell mobilization or collection is required, and patients will receive conditioning directly.

Biological: - C-CAR088

C-CAR088 is an BCMA targeted Chimeric Antigen Receptor-T cell product. Patients will receive C-CAR088 single dose infusion 3 days after ASCT. The dose level of C-CAR088 will be determined by the investigator.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Tianjin, Tianjin, China




Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin, 300020

Site Contact

Dehui Zou, M.D., Ph.D.